Please assess the completion status of the following clinical trial:

Trial Title: Prevention of Anthracycline or Trastuzumab Induced Cardiomyopathy by Metoprolol

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Patients must have confirmed malignancy for which standard regimens of anthracyclines or trastuzumab are being offered as treatment at the University of Maryland Greenebaum Cancer Center. Patients must either receive 4 cycles of anthracycline for a total dose of 240 mg/m2 or six cycles of TAC for a total dose of 300 mg/m2 or trastuzumab.~2. Age \> 18 years~3. Ability to understand and willingness to sign a written informed consent document.~4. Women of childbearing potential may participate in this study only if they have a negative pregnancy test and agree not to become pregnant during the study. Woman of childbearing potential must use an effective method of birth control such as hormonal contraceptives (oral and implant) condoms, diaphragms, spermicidal foam or jelly, surgical (hysterectomy or tubal ligation) or intrauterine device.~Exclusion Criteria:~1. Patients who have established dilated or restrictive cardiomyopathy with EF \< 40 %.~2. Patients with severe mitral or aortic valve disease (valve area \<1cm squared).~3. Patients who have any contraindication to metoprolol, in particular bradycardia with HR \< 50, or severe reactive pulmonary disease such as asthma. Patients who take mibefradil or psychiatric drugs (such as phenothiazines including chlorpromazine and thioridazine) will also be excluded from the study as they have serious interactions with beta-blockers~4. Patients who have untreated thyroid function disorder.~5. Pregnant and nursing women are excluded from this study because of potential risk for adverse events to the fetus.~6. Patients with any impediment to swallowing tablets would be excluded.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Metoprolol (Type: ACTIVE_COMPARATOR): Receiving metoprolol
- Control (Type: NO_INTERVENTION): Not receiving metoprolol

Based on this trial design, predict the completion outcome and termination type (if applicable).